Arrowhead Pharmaceuticals (ARWR) Upgraded at ValuEngine

Arrowhead Pharmaceuticals (NASDAQ:ARWR) was upgraded by equities researchers at ValuEngine from a “hold” rating to a “buy” rating in a research note issued on Monday, April 2nd.

Several other brokerages have also commented on ARWR. BidaskClub raised Arrowhead Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Thursday, March 1st. Chardan Capital reaffirmed a “buy” rating and issued a $7.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Monday, February 19th. Cantor Fitzgerald set a $5.00 target price on Arrowhead Pharmaceuticals and gave the company a “neutral” rating in a research note on Monday, February 12th. Jefferies Group began coverage on Arrowhead Pharmaceuticals in a research note on Tuesday, March 27th. They issued a “buy” rating and a $10.00 target price on the stock. Finally, B. Riley began coverage on Arrowhead Pharmaceuticals in a report on Friday, January 5th. They issued a “neutral” rating and a $3.00 price target for the company. Two research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $6.30.

How to Become a New Pot Stock Millionaire

ARWR stock traded up $0.01 during trading on Monday, hitting $6.85. The company had a trading volume of 860,709 shares, compared to its average volume of 1,842,964. Arrowhead Pharmaceuticals has a 1-year low of $1.42 and a 1-year high of $8.09. The stock has a market capitalization of $626.60, a PE ratio of -14.77 and a beta of 2.35. The company has a quick ratio of 3.87, a current ratio of 3.87 and a debt-to-equity ratio of 0.03.



Arrowhead Pharmaceuticals (NASDAQ:ARWR) last announced its quarterly earnings data on Friday, February 9th. The biotechnology company reported ($0.18) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.14) by ($0.04). The business had revenue of $3.51 million during the quarter, compared to analysts’ expectations of $8.71 million. Arrowhead Pharmaceuticals had a negative net margin of 116.17% and a negative return on equity of 42.52%. analysts expect that Arrowhead Pharmaceuticals will post -0.71 earnings per share for the current fiscal year.

In related news, CEO Christopher Richard Anzalone sold 300,000 shares of the company’s stock in a transaction on Thursday, March 15th. The shares were sold at an average price of $7.43, for a total transaction of $2,229,000.00. Following the completion of the sale, the chief executive officer now directly owns 2,194,789 shares of the company’s stock, valued at approximately $16,307,282.27. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Kenneth Allen Myszkowski sold 20,000 shares of the company’s stock in a transaction on Tuesday, March 27th. The stock was sold at an average price of $8.00, for a total transaction of $160,000.00. Following the sale, the chief financial officer now directly owns 330,815 shares of the company’s stock, valued at $2,646,520. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 440,000 shares of company stock valued at $3,266,600. Insiders own 4.60% of the company’s stock.

Large investors have recently bought and sold shares of the business. OppenheimerFunds Inc. boosted its position in Arrowhead Pharmaceuticals by 110.0% in the 4th quarter. OppenheimerFunds Inc. now owns 6,300,000 shares of the biotechnology company’s stock valued at $23,184,000 after buying an additional 3,300,000 shares during the last quarter. Vanguard Capital Wealth Advisors bought a new position in shares of Arrowhead Pharmaceuticals during the fourth quarter worth about $119,000. Allianz Asset Management GmbH lifted its position in shares of Arrowhead Pharmaceuticals by 2.2% during the fourth quarter. Allianz Asset Management GmbH now owns 462,105 shares of the biotechnology company’s stock worth $1,701,000 after purchasing an additional 9,985 shares during the last quarter. Quantitative Investment Management LLC bought a new position in shares of Arrowhead Pharmaceuticals during the fourth quarter worth about $203,000. Finally, Schwab Charles Investment Management Inc. lifted its position in shares of Arrowhead Pharmaceuticals by 10.4% during the third quarter. Schwab Charles Investment Management Inc. now owns 171,249 shares of the biotechnology company’s stock worth $742,000 after purchasing an additional 16,103 shares during the last quarter. 26.88% of the stock is owned by institutional investors.

TRADEMARK VIOLATION WARNING: This report was originally published by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this report on another site, it was illegally stolen and republished in violation of United States and international copyright laws. The original version of this report can be read at https://stocknewstimes.com/2018/04/17/arrowhead-pharmaceuticals-arwr-upgraded-at-valuengine.html.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. Its pre-clinical stage medicines include ARO-HBV to treat chronic hepatitis B virus infection; ARO-AAT for the treatment of liver disease associated with alpha-1 antitrypsin deficiency; ARO-APOC3 and ARO-ANG3 to treat hypertriglyceridemia; ARO-Lung1 for the treatment of an undisclosed pulmonary target; ARO-HIF2 to treat renal cell carcinoma; ARO-F12 for hereditary angioedema and thromboembolic disorders; and ARO-AMG1 for the treatment of an undisclosed genetically validated cardiovascular target.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply